XFOR | tickerfilter.com

Fundamental analysis

Profitability 8%

Dept financing 11%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

12.16%

1 Month

11.86%

3 Months

6.68%

6 Months

22.42%

1 Year

1,263.79%

2 Year

354.65%

Key data

Stock price

$4.15

P/E Ratio

0.00

DAY RANGE

$3.70 - $4.16

EPS

-$4.32

52 WEEK RANGE

$0.17 - $6.63

52 WEEK CHANGE

$1,202.98

MARKET CAP

39.017 M

YIELD

N/A

SHARES OUTSTANDING

87.437 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

2.11

PUBLIC FLOAT

AVERAGE 10 VOLUME

$532,138

AVERAGE 30 VOLUME

$540,824

Company detail

CEO: Paula S. Ragan
Region: US
Website: x4pharma.com
Employees: 80
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor. The company is also developing X4P-002, a CXCR4 antagonist for the. treatment of brain cancers.

XFOR - X4 Pharmaceuticals Inc